A detailed history of Raymond James Trust N.A. transactions in Organon & Co. stock. As of the latest transaction made, Raymond James Trust N.A. holds 15,495 shares of OGN stock, worth $279,994. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,495
Previous 16,307 4.98%
Holding current value
$279,994
Previous $306,000 4.58%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

SELL
$17.45 - $21.96 $14,169 - $17,831
-812 Reduced 4.98%
15,495 $320,000
Q1 2024

Apr 24, 2024

BUY
$13.78 - $18.8 $33,609 - $45,853
2,439 Added 17.59%
16,307 $306,000
Q4 2023

Jan 10, 2024

BUY
$10.95 - $17.32 $10,763 - $17,025
983 Added 7.63%
13,868 $199,000
Q3 2023

Nov 14, 2023

SELL
$16.59 - $23.77 $364 - $522
-22 Reduced 0.17%
12,885 $223,000
Q2 2023

Aug 15, 2023

BUY
$19.27 - $24.63 $12,140 - $15,516
630 Added 5.13%
12,907 $269,000
Q1 2023

May 03, 2023

SELL
$21.42 - $32.08 $3,213 - $4,812
-150 Reduced 1.21%
12,277 $289,000
Q4 2022

Feb 02, 2023

SELL
$23.31 - $28.61 $13,030 - $15,992
-559 Reduced 4.3%
12,427 $347,000
Q3 2022

Oct 31, 2022

SELL
$23.4 - $34.25 $87,282 - $127,752
-3,730 Reduced 22.31%
12,986 $304,000
Q2 2022

Jul 14, 2022

SELL
$31.66 - $38.9 $30,615 - $37,616
-967 Reduced 5.47%
16,716 $564,000
Q1 2022

May 12, 2022

SELL
$30.45 - $39.36 $23,751 - $30,700
-780 Reduced 4.22%
17,683 $617,000
Q4 2021

Jan 31, 2022

SELL
$28.67 - $37.13 $48,022 - $62,192
-1,675 Reduced 8.32%
18,463 $562,000
Q3 2021

Oct 18, 2021

SELL
$28.63 - $35.64 $172,925 - $215,265
-6,040 Reduced 23.07%
20,138 $660,000
Q2 2021

Jul 20, 2021

BUY
$28.45 - $38.0 $744,764 - $994,764
26,178 New
26,178 $792,000

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $4.6B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track Raymond James Trust N.A. Portfolio

Follow Raymond James Trust N.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Trust N.A., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Trust N.A. with notifications on news.